ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
H01CB02 | B | Octreotide (acetate) - 30mg | 5849/388 | 218904/10 | SANDOSTATIN LAR | 30mg | 1 | Injectable powder for suspension+diluent | IM | Khalil Fattal & Fils S.A.L. | Sandoz GmbH | Austria | L.L | 10.71 | E1 | Novartis Pharma AG | Switzerland | 2/5/2024 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
H01CB02 | B | Octreotide (acetate) - 30mg | 5849 | 218904/10 | SANDOSTATIN LAR | 30mg | 1 | Injectable powder for suspension+diluent | IM | Khalil Fattal & Fils S.A.L. | Sandoz GmbH | Austria | 52,675,605 L.L | 10.71 | E1 | Novartis Pharma AG | Switzerland | 2/5/2024 | 0 |